Edition:
United States

aTyr Pharma Inc (LIFE.O)

LIFE.O on Nasdaq

3.50USD
23 Mar 2017
Change (% chg)

$0.05 (+1.45%)
Prev Close
$3.45
Open
$3.50
Day's High
$3.50
Day's Low
$3.40
Volume
34,437
Avg. Vol
236,364
52-wk High
$5.47
52-wk Low
$2.10

LIFE.O

Chart for LIFE.O

About

aTyr Pharma, Inc. is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology, a discovered set of physiological modulators. The Company focuses on the development of Physiocrine-based... (more)

Overall

Beta: --
Market Cap(Mil.): $81.93
Shares Outstanding(Mil.): 23.75
Dividend: --
Yield (%): --

Financials

  LIFE.O Industry Sector
P/E (TTM): -- 48.09 29.63
EPS (TTM): -2.44 -- --
ROI: -61.05 -2.54 13.01
ROE: -65.06 5.17 14.16

BRIEF-aTyr Pharma qtrly net loss per share attributable to common stockholders $0.53

* Atyr pharma -continues to expect that its cash, cash equivalents and investments will be sufficient to fund its anticipated operations into q3 of 2018

Mar 16 2017

BRIEF-Atyr Pharma reports issuance of U.S. patent that extends patent protection of physiocrines

* Atyr Pharma announces issuance of U.S. patent that extends patent protection of physiocrines derived from 20 out of 20 human TRNA synthetases Source text for Eikon: Further company coverage:

Mar 15 2017

BRIEF-Atyr Pharma receives EMA orphan drug designation for the treatment of limb girdle muscular dystrophy with resolaris

* Atyr Pharma receives ema orphan drug designation for the treatment of limb girdle muscular dystrophy with resolaris™ Source text for Eikon: Further company coverage:

Mar 03 2017

BRIEF-Atyr Pharma receives U.S. FDA orphan drug designation for the treatment of limb girdle muscular dystrophy with Resolaris

* Atyr Pharma Receives U.S. FDA orphan drug designation for the treatment of limb girdle muscular dystrophy with Resolaris™ Source text for Eikon: Further company coverage:

Feb 28 2017

BRIEF-Ecor1 Capital reports 8.3 pct passive stake in Atyr Pharma

* Ecor1 Capital LLC reports 8.3 percent passive stake in Atyr Pharma Inc as of Jan 18 - SEC filing Source text: (http://bit.ly/2kkPDsu) Further company coverage:

Jan 30 2017

BRIEF-FDA grants fast track designation for aTyr's Resolaris

* Fda grants fast track designation for aTyr's Resolaris to treat limb girdle muscular dystrophy 2b and removes partial clinical hold for Resolaris

Jan 18 2017

BRIEF-Atyr Pharma enters into $20 million credit facility

* Intends to use additional capital to pay off existing indebtedness

Nov 21 2016

BRIEF-Atyr Pharma reports Q3 loss per share of $0.58

* Qtrly net loss per share attributable to common stockholders $0.58

Nov 14 2016

BRIEF-Atyr Pharma receives FDA fast track designation for Resolaris to treat FSHD

* Atyr Pharma receives FDA fast track designation for Resolaris to treat facioscapulohumeral muscular dystrophy (FSHD)

Oct 24 2016

More From Around the Web

Earnings vs. Estimates